1Peixoto JA, Teles BC, Castro EE et al. Vincristine delays gastric emptying and gastrointestinal transit of liquid in awake rats[J]. Braz J Med Biol Res, 2009, 42(6): 567-573.
2Sharma RK. Vincristine and gastrointestinal transit[J]. Gastroenterology, 1988, 95(5): 1435-1436.
3Legha SS. Vincristine neurotoxicity. Pathophysiology and management[J]. Med Toxicol, 1986, 1(6): 421-427.
4Cassidy J, Misset JL. Oxaliplatin-related side effects: char- acteristics and management[J]. Semin Oncol, 2002, 29(5 Suppl 15): 11-20.
5Twelves C. Xeloda in Adjuvant Colon Cancer Therapy (X- ACT) trial: overview of efficacy, safety, and cost-effective- ness[J]. Clin Colorectal Cancer, 2006, 6(4): 278-287.
6Bosnjak SM, Neskovic-Konstantinovic ZB, Radulovic SS, et al. High efficacy of a single oral dose of ondanse- tron 8 mg versus a metoclopramide regimen in the pre- vention of acute emesis induced by fluorouracil, doxoru- bicin and cyclophosphamide (FAC) chemotherapy for breast cancer[J]. J Chemother, 2000, 12(5): 446-453.
7Sanger GJ, Wardle KA. Constipation evoked by 5-HT3- receptor antagonism: evidence for heterogeneous effica- cy among different antagonists in guinea-pigs[J]. J Pharm Pharmacol, 1994, 46(8): 666-670.
8Ng TL, Clemons M, Hutton B, et al. Aprepitant versus dexamethasone to prevent delayed emesis after chemo- therapy[J]. J Clin Oncol, 2014, 32(20): 2184-2185.
9Albany C, Brames M J, Fausel C, et al. Randomized, dou- ble-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexa- methasone in patients with germ cell tumors receiving 5- day cisplatin combination chemotherapy regimens: a hoosier oncology group study[J]. J Clin Oncol, 2012, 30 (32): 3998-4003.
10Ahmedzai SH, Boland J. Constipation in people pre- scribed opioids[J]. Clin Evid (Online), 2010, 2010.
